 LA JOLLA, Calif, Nov. 09, 2020 GLOBE NEWSWIRE -- INmune Bio, Inc. NASDAQ: INMB the, Company, a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, announced today that the first patient has been dosed in its Phase 2 clinical trial evaluating QuellorTM for the treatment of pulmonary complications from COVID-19. QuellorTM is a selective soluble Tumor Necrosis Factor sTNF inhibitor designed to potentially prevent the progression of immune mediated pulmonary complications resulting from SARS-CoV-2 viral infection. 